目的 对比替吉奥联合阿帕替尼与单独应用替吉奥治疗晚期胃癌患者的临床疗效分析。方法 选取2016年6月-2017年 6月我院收治的胃癌晚期患者60例，并采用数字表法随机分组为观察组和对照组，各30例。观察组患者给予替吉奥 联合阿帕替尼治疗，对照组患者给予单药替吉奥治疗，观察两组患者治疗后的临床疗效以及不良反应发生情况。结 果 治疗后，观察组患者的总有效率（93.33%）明显高于对照组的总有效率（63.33%）；对照组患者的不良反应发 生率（33.33%）明显高于观察组的不良反应发生率（6.67%），差异均具有统计学意义（P<0.05）。结论 替吉奥联 合阿帕替尼应用于晚期胃癌患者可有效提升患者的临床疗效，且其所发生的毒副反应可耐受，值得推广。

Objective To investigate the clinic effect between Tegafur Gimeracil Otera combined with apatinib and single-drug Tegafur Gimeracil Otera in treating advanced gastric cancer. Methods 60 cases with advanced gastric cancer in our hospital from June 2016 to June 2017 were selected and divided into the observation group and the control group according to number table method, 30 cases in each group. The observation group was given Tegafur Gimeracil Otera combined with apatinib and the control group was given single-drug Tegafur Gimeracil Otera, clinic effect and adverse reactions of the two groups after treatment were observed. Results After treatment, total efficiency of the observation group (93.33%) was significantly higher than that of the control group (63.33%), adverse reaction rate of the control group (33.33%) was significantly higher than that of the observation group (6.67%), the difference was statistic significant (P<0.05). Conclusion Tegafur Gimeracil Otera combined with apatinib in treating advanced gastric cancer can improve clinic effect, toxic and side effect are tolerable, it is worthy of promotion.